Prolonged erection is a rare problem in urology but it must be treated effectively. The most common etiological factor is intracavernosal vasoactive agent injection for diagnosis or treatment of erectile dysfunction. The aim of this study was to evaluate the ef®cacy of intracavernosal adrenalin injection alone in the treatment of priapism. Nineteen patients with prolonged erection were evaluated. Seventeen out of the 19 prolonged erections were due to intracavernosal vasoactive agent injection and the remaining two were idiopathic. In all cases 2 ml adrenalin (1a100 000) was injected in each cavernosal body. In the patients who did not respond to the ®rst injection, repeated adrenalin injections were performed at 20 min intervals. Blood pressure and heart rate were monitored during the injections. Detumescence was achieved in ten (53%) patients after the ®rst injection. Repeated adrenalin injections (2 ± 5 injections) were required in nine patients and eight (42%) of them achieved detumescence. Only one (5%) patient who had 26-h prolonged erection could not achieve detumescence. There was no signi®cant difference in blood pressure and heart rate during the monitoring of the patients when compared to the initial values. No standard treatment method has yet been described for prolonged erection. Repeated aspirations and irrigations for treatment of prolonged erection are problematical applications both for patients and urologist. Intracavernosal adrenalin injection alone can be used with high ef®cacy and safety for the treatment of prolonged erection especially in patients with a short duration of erection.
Introduction
Priapism is prolonged and painful erection caused by various etiological factors. In order to identify a prolonged erection as priapism it must last at least 4 h. 1 In these cases, erection is maintained not necessarily with sexual stimulation and detumescence cannot be achieved with ejaculation. Priapism may occur at all ages, and can even occur in impotent patients. During priapism, the erection is limited to the cavernous bodies, not affecting the corpus spongiosum or glans penis. 2, 3 Psychotropic, antihypertensive and anticoagulant drugs, leukemia, sickle cell anaemia, penile trauma, pelvic infections and intracavernosal vasoactive agent injection (papaverine, papaverine-phentolamine, PGE1 etc) can be the etiological cause. 4 Priapism may also occur idiopathically. 5 Priapism is a medical emergency and must be resolved immediately. Various treatment methods for priapism are currently in use. In this prospective study we aimed to evaluate the results of intracavernosal adrenalin injection alone for the treatment of priapism.
Patients and methods
Nineteen patients presenting with prolonged and painful erections between December 1997 and November 1998 were included in the study. The ages of patients ranged from 26 to 51 y (mean age 35 y). The etiologic factor was intracavernosal vasoactive agent injection in 17 patients and it was idiopathic in two patients. The duration of erection ranged from 4 to 29 h (mean 7 h). Using a 23 G needle 2 ml of 1a100 000 adrenaline solution was injected in to each cavernous body. Repeated injections were performed up to ®ve times in patients who did not achieve detumescence in a period of 20 min after the ®rst injection. Etiologic factors, duration of erection and number of injections performed are summarized in Table 1 .
Wilcoxon test was used for statistical analysis of hemodynamic variables.
Results
Detumescence was produced in ten patients (53%) with the ®rst injection, the remaining patients required additional injections; two injections in six patients (32%), three injections to one patient (5%) and four injections to one patient (5%). In one patient (5%) durable detumescence could not be achieved with ®ve repeated injections, and priapism lasted after aspiration and irrigation in this patient. This patient had had a prolonged erection for 26 h when admitted to our clinic. Eighteen of the 19 patients (95%) achieved detumescence with intracavernosal adrenalin injections. The ef®cacy of adrenalin injection is shown in Table 2 .
Patients were monitored during the procedure and for a period of 30 min after completion of the injections. There was no signi®cant difference in heart rate, cardiac rhythm and blood pressure during monitorization when compared to the initial values (P`0.05).
Patients were re-evaluated by questioning their present sexual activity, two months after the treatment in order to identify any possible erectile dysfunction that may have occurred following priapism. None of the patients complained about erectile dysfunction, including the one who had presented with 29-h priapism.
Discussion
In the physiology of erection, appropriate arterial and venous anatomy and neurological stimulation causing relaxation of smooth muscles of arterioles and lacunar sinusoids are needed. 6 ± 8 Thus the blood ow to lacunar sinusoids rapidly increases and, by the compression of emissary veins, venous out¯ow decreases and erection occurs. 9 When erection persists, priapism occurs. In detumescence, the hemodynamic processes work in reverse; the sympathetic nervous system leads to vasoconstriction in penile sinusoids causing decreased arterial¯ow, then decreased venous pressure causes emissary veins to open and venous¯ow re-establishes. 10 There is no standard therapy for priapism. However, different treatment alternatives such as cold or pressure application to penile shaft, prostate massage, anesthetics, sedatives, oral terbutalin, metaraminol, ethylchloride spray, aspiration of cavernosal blood, aspiration and irrigation (with isotonic solutions or with solutions containing alpha-adrenergic drugs) have been used for the treatment of prolonged erections. Surgical interventions are also available for some resistant cases.
Alpha-adrenergic blocker drugs have been used in the diagnosis and treatment of patients with erectile dysfunction to induce erection. From this point of view alpha-adrenergic agonist drugs could be used in the treatment of prolonged erection. 11 Adrenalin has also some beta-adrenergic activity beside its alpha-adrenergic agonist activity. Vasodilatation due to beta-adrenergic activity on the venous system may also help to produce detumescence.
Alpha adrenergic agonist drugs such as ethylephrine, phenylephrine and epinephrine have been used for priapism in different studies. Either intracavernosal injection, or aspiration and irrigation of cavernosal bodies with these drugs have both been used in the management of priapism or in resolving intra-operative rigidity.
Injection of diluted alpha-agonist drugs following dark venous blood aspiration from the corpus cavernosa has been applied to patients with priapism in different studies and 75 ± 100% success rates were reported. 12 ± 14 In a study in which no blood aspiration was performed, 88% of the patients with priapism were reported to have detumescence after injection of intracavernosal phenylephrine. 15 In a study by Zappala et al, 16 ®ve patients having intra-operative rigid erections were administrated diluted epinephrine and lidocaine solution and Intracavernosal adrenalin injection in priapism D Keskin et al rigidity was resolved in all cases. However, these patients cannot be regarded as having true priapism. Aspiration and irrigation of cavernosal bodies are problematical methods both for the patient and the physician, consequently they are not applied willingly, and have also produced some morbidity.
Creating spongiocavernosal anastomosis between the glans penis and corpus cavernosum (Winter operation) and between the corpus cavernosum and corpus spongiosum of the urethra (Quackles' operation) are effective methods but require an operating theatre. Also corpus cavernosum blood can be diverted to the systemic circulation by saphenocavernosal shunt operation. Some authors advise immediate shunt operations primarily to avoid delays by using conservative methods and to avoid ischaemia and thrombosis. However, applying an operative procedure without an exact indication is not rational and it must only be applied to patients who cannot achieve detumescence using other methods.
Patients who developed priapism after intracavernosal vasoactive drug injection for diagnosis and treatment of erectile dysfunction, can easily tolerate intracavernosal adrenalin injection in order to achieve detumescence. However, this easy and minimal invasive method could also be a preferable ®rst line treatment option for patients who are suffering from priapism with various etiologies.
In our study group 17 of 19 patients had erection durations for less than 9 h and detumescence was achieved with one injection in ten patients, and with two injections in six patients. Successful treatment was established in 85% of patients within 20 min. In one patient detumescence occurred after three injections. Achieving detumescence after four adrenalin injections in one out of two patients, whose erection duration was longer than 24 h is exceptional. This patient admitted with erection duration of 29 h and detumescence occurred in 1.5 h, therefore we cannot discuss any iatrogenic delay that may cause ischaemia or thrombosis. In the other patient who had 26-h erection, detumescence could not be achieved after ®ve injections and penile aspiration and irrigation with isotonic solution was performed.
Detumescence was achieved with one intracavernosal adrenalin injection in 53% of the patients and with repeated injections in 42% of the patients. The overall success rate was 95%.
Cavernosal blood gas analysis, which could be used for investigating ischaemic and thrombotic events due to priapism, was not performed in our patients. However, no erectile dysfunction occurred in our patients after treatment, supporting the hypothesis that intracavernosal adrenalin injection can be used as the ®rst line treatment in priapism.
In our study we used only diluted epinephrine. The duration of rigidity was quite long and, according to Medline records, this is the only report giving the results of epinephrine administration in priapism without performing aspiration and irrigation.
In this study, single intracavernosal adrenalin injection has a success rate of over 50%, especially in patients with a short erection duration, and overall success rate with repeated injections is 95%, thus the method performed in the current study is an effective treatment option in priapism. Other advantages of this treatment are the no signi®cant difference in hemodynamic parameters and the simplicity of application.
